Joshua Kesterson, MD
Gynecologic Oncology · Newport, PANPI 1922142165
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $624,821 of the $839,492 with a category attached, or 74.4%. 17 manufacturers reported payments, led by GSK at 48.1% of the total. Among gynecologic oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $1175.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$404K
- Clovis Oncology, Inc.$123K
- Genmab U.S., Inc.$73K
- Seagen Inc.$61K
- Tesaro, Inc.$42K
- Pfizer$40K
- plus $96K from 11 others
Across 3 payments — averaging $7866.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$21K
- AbbVie$3K
What the payments were for
- Consulting fees$109,06113%
- Speaking & faculty fees$624,82174%
- Travel & lodging$83,48910%
- Food & beverage$19,0982%
- Education$3,0230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 286 | $404,118 |
| Clovis Oncology, Inc. | 102 | $122,578 |
| Genmab U.S., Inc. | 64 | $72,849 |
| Seagen Inc. | 47 | $61,487 |
| Tesaro, Inc. | 47 | $42,201 |
| Pfizer | 28 | $39,930 |
| Baxter Healthcare | 51 | $27,088 |
| Eisai Inc. | 29 | $26,152 |
| Merck | 24 | $24,544 |
| AstraZeneca | 16 | $14,182 |
| Medtronic | 5 | $3,038 |
| Immunogen, Inc. | 2 | $640 |
| AbbVie | 5 | $388 |
| Dilon Technologies, Inc. | 1 | $172 |
| Biom'up SA | 3 | $71 |
| Johnson & Johnson | 3 | $34 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$839,492 in reported general payments places this provider in the 95th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 43 | $1,116 |
| Letrozole | 16 | $194 |
| Oxycodone Hcl | 13 | $45 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Newport
- Thomas KrivakPittsburgh$1.6M
- Mark ShahinHershey$914K
- Charles DuntonWynnewood$309K
- M ThomasAllentown$257K
- Alexander OlawaiyePittsburgh$226K
- John NakayamaPittsburgh$194K
- Emily KoPhiladelphia$78K
- Anna SmithPhiladelphia$77K
- Georges ChamounScranton$63K
- Robert BurgerPhiladelphia$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.